These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33573996)

  • 1. Cannabinoids for Agitation in Alzheimer's Disease.
    Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
    Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
    Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.
    Trzepacz PT; Yu P; Bhamidipati PK; Willis B; Forrester T; Tabas L; Schwarz AJ; Saykin AJ;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S95-S104.e1. PubMed ID: 23253778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
    Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
    Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "Cannabinoids for Agitation in Alzheimer's Disease".
    Goveas JS
    Am J Geriatr Psychiatry; 2021 Dec; 29(12):1264-1266. PubMed ID: 33839012
    [No Abstract]   [Full Text] [Related]  

  • 10. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
    Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
    Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
    Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):289-303. PubMed ID: 38822731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.
    Senanarong V; Cummings JL; Fairbanks L; Mega M; Masterman DM; O'Connor SM; Strickland TL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):14-20. PubMed ID: 14560060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can antidepressant medication relieve agitation in Alzheimer's disease?
    Porsteinsson AP; Smith JS; Keltz MA; Antonsdottir IM
    Expert Rev Neurother; 2014 Sep; 14(9):969-71. PubMed ID: 25148535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral THC: CBD cannabis extract in main symptoms of Alzheimer disease: agitation and weight loss.
    Palmieri B; Vadalà M
    Clin Ter; 2023; 174(1):53-60. PubMed ID: 36655645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia.
    Sherman C; Ruthirakuhan M; Vieira D; Lanctôt KL; Herrmann N
    Curr Opin Psychiatry; 2018 Mar; 31(2):140-146. PubMed ID: 29256923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
    Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
    CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia.
    Van der Mussele S; Le Bastard N; Saerens J; Somers N; Mariën P; Goeman J; De Deyn PP; Engelborghs S
    Aging Ment Health; 2015; 19(3):247-57. PubMed ID: 24962058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?
    Rosenberg PB; Nowrangi MA; Lyketsos CG
    Mol Aspects Med; 2015; 43-44():25-37. PubMed ID: 26049034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.